Updated Guidelines for TB Screening, Treatment in Health Care Workers
Guidelines have been updated for screening and treatment for tuberculosis infection among health care personnel.
Emerging Treatments
Early Extended Pamidronate May Help Reduce Chronic Nonbacterial Osteomyelitis Activity
Study showed that pamidronate might contribute to clinical improvement and improvement of radiologic outcome in chronic nonbacterial osteomyelitis, however, relapses were frequent.
Procalcitonin-Guided Care as Effective as Guideline-Based Clinical Assessment in CAP
Approaches to emergency department community-acquired pneumonia care can incorporate either guideline-based serial clinical assessment or procalcitonin-driven strategies.
Glecaprevir/Pibrentasvir Approved to Treat All 6 Genotypes of HCV in Pediatric Patients
The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
First Clinical Development Candidate of Cidara’s Influenza Program Announced
Data supporting the selection of the antiviral conjugate CB-012 as Cidara Therapeutics Incorporated’s first clinical development candidate from the company’s influenza program.
Glecaprevir + Pibrentasvir: Efficacious, Safe for HCV After Liver Transplantation
An 8- or 12-week regimen of glecaprevir and pibrentasvir is efficacious and safe in patients with HCV infection after liver transplantation.
NDA for Once-Monthly Injectable HIV Treatment Submitted to FDA
The NDA for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for HIV has been submitted.
Treatment for Severe Malaria Receives Breakthrough Therapy Status
The Food and Drug Administration has granted an investigational treatment for severe malaria Breakthrough Therapy designation.
UB-421 Monotherapy Maintains HIV Viral Suppression
Suppression maintained for up to 16 weeks in HIV-infected undergoing analytic treatment interruption
Dual Therapy With Rilpivirine and Boosted Darunavir Is Effective in PLWHIV
Rilpivirine plus boosted-darunavir dual therapy may be effective and safe in patients with advanced HIV.
Next post in HIV/AIDS
